Bank Of New York Mellon Corp Day One Biopharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$12.75 - $23.41 $1.42 Million - $2.61 Million	111,631 New	111,631 $1.49 Billion
Q4 2022 Feb 14, 2023	BUY	$18.77 - $22.0 $1.89 Million - $2.21 Million	100,501 New	100,501 $2.16 Million
Q3 2022 Nov 14, 2022	BUY	$16.44 - $26.57 $635,915 - $1.03 Million	38,681 Added 60.87%	102,223 $2.05 Million
Q2 2022 Aug 15, 2022	BUY	$5.72 - $17.9 $34,617 - $108,330	6,052 Added 10.53%	63,542 $1.14 Million
Q1 2022 May 11, 2022	BUY	$9.12 - $17.47 $230,279 - $441,117	25,250 Added 78.32%	57,490 $570,000
Q4 2021 Feb 11, 2022	BUY	$15.65 - $26.33 $85,214 - $143,366	5,445 Added 20.32%	32,240 $543,000
Q3 2021 Nov 12, 2021	BUY	$20.0 - $27.92 $535,900 - $748,116	26,795 New	26,795 $635,000

178

84M

144K

218K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $940M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.